Sinopharm Group Co

Sinopharm Group Co EBIT per Share

The EBIT per Share of Sinopharm Group Co (1099.HK) as of Oct 22, 2026 is 5.98 CNY. In the previous year, EBIT per Share was 6.05 CNY — a change of -1.16% (lower).

EBIT per Share

5.98CNY

YoY

-1.16%

Last updated:

EBIT per Share of Sinopharm Group Co is 2025 5.98 CNY. EBIT per Share of Sinopharm Group Co was 2024 6.05 CNY. It decreases by -1.16% lower compared to the previous year.

The Sinopharm Group Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
7.35 CNY
Jan 1, 2022
7.69 CNY
Jan 1, 2023
7.55 CNY
Jan 1, 2024
6.05 CNY
Jan 1, 2025
5.98 CNY
Jan 1, 2026 (e)
3.98 CNY
Jan 1, 2027 (e)
3.63 CNY
Jan 1, 2028 (e)
3.88 CNY
The Sinopharm Group Co EBIT per Share history
YEAREBIT per ShareYoY
est3.88CNY+6.83%
est3.63CNY-8.74%
est3.98CNY-33.48%
5.98CNY-1.16%
6.05CNY-19.80%
7.55CNY-1.86%
7.69CNY+4.59%
7.35CNY+10.99%
6.62CNY+4.80%
6.32CNY+4.81%
6.03CNY+29.32%
4.66CNY+1.08%
4.61CNY+19.10%
3.87CNY+10.71%
3.50CNY+27.46%
2.75CNY+16.52%
2.36CNY+31.16%
1.80CNY+45.09%
1.24CNY+24.12%
1.00CNY+19.69%
0.83CNY+48.49%
0.56CNY+64.36%
0.34CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinopharm Group Co Stock analysis

What does Sinopharm Group Co do? Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinopharm Group Co stock

EBIT per Share of Sinopharm Group Co is 5.98 CNY in 2025.

EBIT per Share of Sinopharm Group Co changed from 6.05 CNY to 5.98 CNY, representing a -1.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Sinopharm Group Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sinopharm Group Co

All Key Metrics — Sinopharm Group Co